CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2-breast cancer: A meta-analysis of randomized controlled trials

被引：11
作者：
Wang, Liquan [1 ]
Gao, Shuyan [2 ]
Li, Dianfang [2 ]
Ran, Xuehong [2 ]
Sheng, Zhixin [2 ]
Wu, Wei [3 ]
Yang, Xiaojing [2 ]
机构：
[1] Weifang Peoples Hosp, Dept Breast Surg, Weifang, Peoples R China
[2] Weifang Peoples Hosp, Dept Hematol, Weifang, Peoples R China
[3] Weifang Peoples Hosp, Dept Stomatol, Weifang, Peoples R China
来源：
BREAST JOURNAL | 2020年 / 26卷 / 07期
关键词：
abemaciclib; breast cancer; palbociclib; ribociclib; ESTROGEN-RECEPTOR;
D O I：
10.1111/tbj.13703
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1439 / 1443
页数：5
相关论文
共 8 条
[1]   CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials [J].
Deng, Yunfu ;
Ma, Guangzhi ;
Li, Wen ;
Wang, Ting ;
Zhao, Yaqin ;
Wu, Qiang .
CLINICAL BREAST CANCER, 2018, 18 (05) :E943-E953
[2]   The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study [J].
Finn, Richard S. ;
Crown, John P. ;
Lang, Istvan ;
Boer, Katalin ;
Bondarenko, Igor M. ;
Kulyk, Sergey O. ;
Ettl, Johannes ;
Patel, Ravindranath ;
Pinter, Tamas ;
Schmidt, Marcus ;
Shparyk, Yaroslav ;
Thummala, Anu R. ;
Voytko, Nataliya L. ;
Fowst, Camilla ;
Huang, Xin ;
Kim, Sindy T. ;
Randolph, Sophia ;
Slamon, Dennis J. .
LANCET ONCOLOGY, 2015, 16 (01) :25-35
[3]   PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro [J].
Finn, Richard S. ;
Dering, Judy ;
Conklin, Dylan ;
Kalous, Ondrej ;
Cohen, David J. ;
Desai, Amrita J. ;
Ginther, Charles ;
Atefi, Mohammad ;
Chen, Isan ;
Fowst, Camilla ;
Los, Gerret ;
Slamon, Dennis J. .
BREAST CANCER RESEARCH, 2009, 11 (05)
[4]   Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer [J].
Hortobagyi, G. N. ;
Stemmer, S. M. ;
Burris, H. A. ;
Yap, Y. S. ;
Sonke, C. S. ;
Paluch-Shimon, S. ;
Campone, M. ;
Petrakova, K. ;
Blackwell, K. L. ;
Winer, E. P. ;
Janni, W. ;
Verma, S. ;
Conte, P. ;
Arteaga, C. L. ;
Cameron, D. A. ;
Mondal, S. ;
Su, F. ;
Miller, M. ;
Elmeliegy, M. ;
Germa, C. ;
O'Shaughnessy, J. .
ANNALS OF ONCOLOGY, 2018, 29 (07) :1541-1547
[5]   Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer [J].
Im, S. -A. ;
Lu, Y. -S. ;
Bardia, A. ;
Harbeck, N. ;
Colleoni, M. ;
Franke, F. ;
Chow, L. ;
Sohn, J. ;
Lee, K. -S. ;
Campos-Gomez, S. ;
Villanueva-Vazquez, R. ;
Jung, K. -H. ;
Chakravartty, A. ;
Hughes, G. ;
Gounaris, I. ;
Rodriguez-Lorenc, K. ;
Taran, T. ;
Hurvitz, S. ;
Tripathy, D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :307-316
[6]   Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression [J].
Lindstrom, Linda Sofie ;
Karlsson, Eva ;
Wilking, Ulla M. ;
Johansson, Ulla ;
Hartman, Johan ;
Lidbrink, Elisabet Kerstin ;
Hatschek, Thomas ;
Skoog, Lambert ;
Bergh, Jonas .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2601-2608
[7]   CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials [J].
Messina, Carlo ;
Cattrini, Carlo ;
Buzzatti, Giulia ;
Cerbone, Luigi ;
Zanardi, Elisa ;
Messina, Marco ;
Boccardo, Francesco .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (01) :9-21
[8]   Treating cancer with selective CDK4/6 inhibitors [J].
O'Leary, Ben ;
Finn, Richard S. ;
Turner, Nicholas C. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) :417-430
1